Research progress on the non-specific protective effect of BCG

doi:10.3969/j.issn.1000-6621.2020.10.020

Abstract

Abstract:

In addition to the protection against tuberculosis, bacillus Calmette-Guérin (BCG) can induce non-specific protective effect (NSE). The results obtained by various epidemiological studies showed that BCG can provide certain protection against other pathogen infections and can effectively improve the survival rate of children. Some of those results had been verified by randomized clinical trials. In this review, the author will summarize the related epidemiological research results and the mechanisms of the NSE.

Key words: BCG vaccine, Immunity, innate, Bacterial infections, Coronavirus infections, Non-specific protective effect, T-cell antigen receptor specificity, Review

CHEN Ning, SUN Lin, SHEN A-dong, HE Qiu-shui. Research progress on the non-specific protective effect of BCG[J]. Chinese Journal of Antituberculosis, 2020, 42(10): 1128-1133. doi: 10.3969/j.issn.1000-6621.2020.10.020

Figures/Tables 2

References 59

[1]	Luca S, Mihaescu T. History of BCG Vaccine. Maedica (Buchar), 2013,8(1):53-58.
[2]	Peck M, Gacic-Dobo M, Diallo MS, et al. Global Routine Vaccination Coverage, 2018. MMWR Morb Mortal Wkly Rep, 2019,68(42):937-942. doi: 10.15585/mmwr.mm6842a1. doi: 10.15585/mmwr.mm6842a1 URL pmid: 31647786
[3]	Yamazaki-Nakashimada MA, Unzueta A, Berenise Gámez-González L, et al. BCG: a vaccine with multiple faces. Hum Vaccin Immunother, 2020,16(8):1841-1850. doi: 10.1080/21645515.2019.1706930. doi: 10.1080/21645515.2019.1706930 URL pmid: 31995448
[4]	Shann F. Nonspecific effects of vaccines and the reduction of mortality in children. Clin Ther, 2013,35(2):109-114. doi: 10.1016/j.clinthera.2013.01.007. doi: 10.1016/j.clinthera.2013.01.007 URL pmid: 23375475
[5]	Biering-Sørensen S, Aaby P, Lund N, et al. Early BCG-Denmark and Neonatal Mortality Among Infants Weighing <2500 g: A Randomized Controlled Trial. Clin Infect Dis, 2017,65(7):1183-1190. doi: 10.1093/cid/cix525. doi: 10.1093/cid/cix525 URL pmid: 29579158
[6]	de Bree LCJ, Koeken VACM, Joosten LAB, et al. Non-specific effects of vaccines: Current evidence and potential implications. Semin Immunol, 2018,39:35-43. doi: 10.1016/j.smim.2018.06.002. doi: 10.1016/j.smim.2018.06.002 URL pmid: 30007489
[7]	Berendsen ML, van Gijzel SW, Smits J, et al. BCG vaccination is associated with reduced malaria prevalence in children under the age of 5 years in sub-Saharan Africa. BMJ Glob Health, 2019,4(6):e001862. doi: 10.1136/bmjgh-2019-001862. URL pmid: 31798997
[8]	Redelman-Sidi G, Glickman MS, Bochner BH. The mechanism of action of BCG therapy for bladder cancer--a current perspective. Nat Rev Urol, 2014,11(3):153-162. doi: 10.1038/nrurol.2014.15. URL pmid: 24492433
[9]	Morra ME, Kien ND, Elmaraezy A, et al. Early vaccination protects against childhood leukemia: A systematic review and meta-analysis. Sci Rep, 2017,7(1):15986. doi: 10.1038/s41598-017-16067-0. doi: 10.1038/s41598-017-16067-0 URL pmid: 29167460
[10]	Usher NT, Chang S, Howard RS, et al. Association of BCG Vaccination in Childhood with Subsequent Cancer Diagnoses: A 60-Year Follow-up of a Clinical Trial. JAMA Netw Open, 2019,2(9):e1912014. doi: 10.1001/jamanetworkopen.2019.12014. doi: 10.1001/jamanetworkopen.2019.12014 URL
[11]	Shehadeh N, Etzioni A, Cahana A, et al. Repeated BCG vaccination is more effective than a single dose in preventing diabetes in non-obese diabetic (NOD) mice. Isr J Med Sci, 1997,33(11):711-715. URL pmid: 9434805
[12]	Zuo Z, Qi F, Yang J, et al. Immunization with Bacillus Calmette-Guérin (BCG) alleviates neuroinflammation and cognitive deficits in APP/PS1 mice via the recruitment of inflammation-resolving monocytes to the brain. Neurobiol Dis, 2017,101:27-39. doi: 10.1016/j.nbd.2017.02.001. doi: 10.1016/j.nbd.2017.02.001 URL pmid: 28189498
[13]	Dow CT. Proposing BCG Vaccination for Mycobacterium avium ss. paratuberculosis (MAP) Associated Autoimmune Diseases. Microorganisms, 2020,8(2):212. doi: 10.3390/microorganisms8020212.
[14]	Zimmermann P, Finn A, Curtis N. Does BCG Vaccination Protect Against Nontuberculous Mycobacterial Infection? A Systematic Review and Meta-Analysis. J Infect Dis, 2018,218(5):679-687. doi: 10.1093/infdis/jiy207. doi: 10.1093/infdis/jiy207 URL pmid: 29635431
[15]	World Health Organization. Leprosy. Geneva: World Health Organization, 2019.
[16]	Setia MS, Steinmaus C, Ho CS, et al. The role of BCG in prevention of leprosy: a meta-analysis. Lancet Infect Dis, 2006,6(3):162-170. doi: 10.1016/S1473-3099(06)70412-1. doi: 10.1016/S1473-3099(06)70412-1 URL pmid: 16500597
[17]	World Health Organization. BCG vaccine: WHO position paper, February 2018-Recommendations. Vaccine, 2018,36(24):3408-3410. doi: 10.1016/j.vaccine.2018.03.009. doi: 10.1016/j.vaccine.2018.03.009 URL pmid: 29609965
[18]	Gomes RR, Antunes DE, Dos Santos DF, et al. BCG vaccine and leprosy household contacts: Protective effect and probability to becoming sick during follow-up. Vaccine, 2019,37(43):6510-6517. doi: 10.1016/j.vaccine.2019.08.067. URL pmid: 31500969
[19]	Cunha SS, Alexander N, Barreto ML, et al. BCG revaccination does not protect against leprosy in the Brazilian Amazon: a cluster randomised trial. PLoS Negl Trop Dis, 2008,2(2):e167. doi: 10.1371/journal.pntd.0000167. doi: 10.1371/journal.pntd.0000167 URL pmid: 18270542
[20]	Stanley SJ, Howland C, Stone MM, et al. BCG vaccination of children against leprosy in Uganda: final results. J Hyg (Lond), 1981,87(2):233-248. doi: 10.1017/s002217240006945x.
[21]	Lwin K, Sundaresan T, Gyi MM, et al. BCG vaccination of children against leprosy: fourteen-year findings of the trial in Burma. Bull World Health Organ, 1985,63(6):1069-1078. URL pmid: 2940028
[22]	Bagshawe A, Scott GC, Russell DA, et al. BCG vaccination in leprosy: final results of the trial in Karimui, Papua New Guinea, 1963-79. Bull World Health Organ, 1989,67(4):389-399. URL pmid: 2680140
[23]	Pönnighaus JM, Fine PE, Sterne JA, et al. Efficacy of BCG vaccine against leprosy and tuberculosis in northern Malawi. Lancet, 1992,339(8794):636-639. doi: 10.1016/0140-6736(92)90794-4. doi: 10.1016/0140-6736(92)90794-4 URL pmid: 1347338
[24]	Rodrigues ML, Silva SA, Neto JC, et al. Protective effect of intradermal BCG against leprosy; a case-control study in central Brazil. Int J Lepr Other Mycobact Dis, 1992,60(3):335-339. URL pmid: 1474274
[25]	Baker DM, Nguyen-Van-Tam JS, Smith SJ. Protective efficacy of BCG vaccine against leprosy in southern Mala$\hat{w}$i . Epidemiol Infect, 1993,111(1):21-25. doi: 10.1017/s0950268800056636. doi: 10.1017/s0950268800056636 URL pmid: 8348929
[26]	Karonga Prevention Trial Group. Randomised controlled trial of single BCG, repeated BCG, or combined BCG and killed Mycobacterium leprae vaccine for prevention of leprosy and tuberculosis in Malawi. Lancet, 1996,348(9019):17-24. URL pmid: 8691924
[27]	Lombardi C, Pedrazzani ES, Pedrazzani JC, et al. Protective efficacy of BCG against leprosy in São Paulo. Bull Pan Am Health Organ, 1996,30(1):24-30. URL pmid: 8919722
[28]	Bertolli J, Pangi C, Frerichs R, et al. A case-control study of the effectiveness of BCG vaccine for preventing leprosy in Yangon, Myanmar. Int J Epidemiol, 1997,26(4):888-896. doi: 10.1093/ije/26.4.888. URL pmid: 9279624
[29]	Zodpey SP, Shrikhande SN, Salodkar AD, et al. Effectiveness of bacillus Calmette-Guerin (BCG) vaccination in the prevention of leprosy; a case-finding control study in Nagpur, India. Int J Lepr Other Mycobact Dis, 1998,66(3):309-315. URL pmid: 9934357
[30]	Zodpey SP, Bansod BS, Shrikhande SN, et al. Protective effect of Bacillus Calmette Guerin (BCG) against leprosy: a population-based case-control study in Nagpur, India. Lepr Rev, 1999,70(3):287-294. doi: 10.5935/0305-7518.19990032. doi: 10.5935/0305-7518.19990032 URL pmid: 10603718
[31]	Cunha SS, Rodrigues LC, Pedrosa V, et al. Neonatal BCG protection against leprosy: a study in Manaus, Brazilian Amazon. Lepr Rev, 2004,75(4):357-366. URL pmid: 15682973
[32]	Zodpey SP, Ambadekar NN, Thakur A. Effectiveness of Bacillus Calmette Guerin (BCG) vaccination in the prevention of leprosy: a population-based case-control study in Yavatmal District, India. Public Health, 2005,119(3):209-216. doi: 10.1016/j.puhe.2004.04.007. doi: 10.1016/j.puhe.2004.04.007 URL pmid: 15661132
[33]	Rahete NP, Zodpey SP, Kamble KM. Effectiveness of Bacillus Calmette Guerin (BCG) vaccination in the prevention of leprosy: a population-based case-control study in Raipur, India. Indian J Public Health, 2007,51(2):86-90. URL pmid: 18240467
[34]	Zodpey SP, Shrikhande SN, Kulkarni SW, et al. Scar size and effectiveness of Bacillus Calmette Guerin (BCG) vaccination in the prevention of tuberculosis and leprosy: a case-control study. Indian J Public Health, 2007,51(3):184-189. URL pmid: 18229442
[35]	Düppre NC, Camacho LA, da Cunha SS, et al. Effectiveness of BCG vaccination among leprosy contacts: a cohort study. Trans R Soc Trop Med Hyg, 2008,102(7):631-638. doi: 10.1016/j.trstmh.2008.04.015. doi: 10.1016/j.trstmh.2008.04.015 URL pmid: 18514242
[36]	Yotsu RR, Suzuki K, Simmonds RE, et al. Buruli Ulcer: a Review of the Current Knowledge. Curr Trop Med Rep, 2018,5(4):247-256. doi: 10.1007/s40475-018-0166-2. doi: 10.1007/s40475-018-0166-2 URL pmid: 30460172
[37]	BCG vaccination against mycobacterium ulcerans infection (Buruli ulcer). First results of a trial in Uganda. Lancet, 1969,1(7586):111-115. URL pmid: 4178240
[38]	Phillips RO, Phanzu DM, Beissner M, et al. Effectiveness of routine BCG vaccination on buruli ulcer disease: a case-control study in the Democratic Republic of Congo, Ghana and Togo. PLoS Negl Trop Dis, 2015,9(1):e3457. doi: 10.1371/journal.pntd.0003457. doi: 10.1371/journal.pntd.0003457 URL pmid: 25569674
[39]	Stensballe LG, Nante E, Jensen IP, et al. Acute lower respiratory tract infections and respiratory syncytial virus in infants in Guinea-Bissau: a beneficial effect of BCG vaccination for girls community based case-control study. Vaccine, 2005,23(10):1251-1257. doi: 10.1016/j.vaccine.2004.09.006. doi: 10.1016/j.vaccine.2004.09.006 URL pmid: 15652667
[40]	Arts RJW, Moorlag SJCFM, Novakovic B, et al. BCG Vaccination Protects against Experimental Viral Infection in Humans through the Induction of Cytokines Associated with Trained Immunity. Cell Host Microbe, 2018, 23(1):89-100.e5. doi: 10.1016/j.chom.2017.12.010. doi: 10.1016/j.chom.2017.12.010 URL pmid: 29324233
[41]	Hippmann G, Wekkeli M, Rosenkranz AR, et al. Nonspecific immune stimulation with BCG in Herpes simplex recidivans. Follow-up 5 to 10 years after BCG vaccination. Wien Klin Wochenschr, 1992,104(7):200-204. URL pmid: 1523844
[42]	Podder I, Bhattacharya S, Mishra V, et al. Immunotherapy in viral warts with intradermal Bacillus Calmette-Guerin vaccine versus intradermal tuberculin purified protein derivative: A double-blind, randomized controlled trial comparing effectiveness and safety in a tertiary care center in Eastern India. Indian J Dermatol Venereol Leprol, 2017,83(3):411. doi: 10.4103/0378-6323.193623. doi: 10.4103/0378-6323.193623 URL pmid: 27852999
[43]	Leentjens J, Kox M, Stokman R, et al. BCG Vaccination Enhances the Immunogenicity of Subsequent Influenza Vaccination in Healthy Volunteers: A Randomized, Placebo-Controlled Pilot Study. J Infect Dis, 2015,212(12):1930-1938. doi: 10.1093/infdis/jiv332. doi: 10.1093/infdis/jiv332 URL pmid: 26071565
[44]	Daulatabad D, Pandhi D, Singal A. BCG vaccine for immunotherapy in warts: is it really safe in a tuberculosis endemic area?. Dermatol Ther, 2016,29(3):168-172. doi: 10.1111/dth.12336. doi: 10.1111/dth.12336 URL pmid: 26809285
[45]	de Vrieze J. Can a century-old TB vaccine steel the immune system against the new coronavirus?[R/OL]. [2020-03-23]. https://www.sciencemag.org/news/2020/03/can-century-old-tb-vaccine-steel-immune-system-against-new-coronavirus#.
[46]	Curtis N, Sparrow A, Ghebreyesus TA, et al. Considering BCG vaccination to reduce the impact of COVID-19. Lancet, 2020,395(10236):1545-1546. doi: 10.1016/S0140-6736(20)31025-4. doi: 10.1016/S0140-6736(20)31025-4 URL pmid: 32359402
[47]	Hamiel U, Kozer E, Youngster I. SARS-CoV-2 Rates in BCG-Vaccinated and Unvaccinated Young Adults. JAMA, 2020,323(22):2340-2341. doi: 10.1001/jama.2020.8189. doi: 10.1001/jama.2020.8189 URL pmid: 32401274
[48]	World Health Organization. Bacille Calmette-Guérin (BCG) vaccination and COVID-19. Geneva: World Health Organization, 2020.
[49]	Salem A, Nofal A, Hosny D. Treatment of common and plane warts in children with topical viable Bacillus Calmette-Guerin. Pediatr Dermatol, 2013,30(1):60-63. doi: 10.1111/j.1525-1470.2012.01848.x. URL pmid: 22958215
[50]	Uthayakumar D, Paris S, Chapat L, et al. Non-specific Effects of Vaccines Illustrated Through the BCG Example: From Observations to Demonstrations. Front Immunol, 2018,9:2869. doi: 10.3389/fimmu.2018.02869. doi: 10.3389/fimmu.2018.02869 URL pmid: 30564249
[51]	Kleinnijenhuis J, Quintin J, Preijers F, et al. Long-lasting effects of BCG vaccination on both heterologous Th1/Th17 responses and innate trained immunity. J Innate Immun, 2014,6(2):152-158. doi: 10.1159/000355628. doi: 10.1159/000355628 URL pmid: 24192057
[52]	Ugolini M, Gerhard J, Burkert S, et al. Recognition of microbial viability via TLR8 drives TFH cell differentiation and vaccine responses. Nat Immunol, 2018,19(4):386-396. doi: 10.1038/s41590-018-0068-4. doi: 10.1038/s41590-018-0068-4 URL pmid: 29556002
[53]	Ritz N, Mui M, Balloch A, et al. Non-specific effect of Bacille Calmette-Guérin vaccine on the immune response to routine immunisations. Vaccine, 2013,31(30):3098-3103. doi: 10.1016/j.vaccine.2013.03.059. doi: 10.1016/j.vaccine.2013.03.059 URL pmid: 23583897
[54]	Netea MG, Joosten LA, Latz E, et al. Trained immunity: A program of innate immune memory in health and disease. Science, 2016, 352(3284): aaf1098. doi: 10.1126/science.aaf1098.
[55]	Loenhout J, de Jong D, Stunnenberg HG, et al. Bacille Calmette-Guerin induces NOD2-dependent nonspecific protection from reinfection via epigenetic reprogramming of monocytes. Proc Natl Acad Sci U S A, 2012,109(43):17537-17542. doi: 10.1073/pnas.1202870109. doi: 10.1073/pnas.1202870109 URL pmid: 22988082
[56]	Bekkering S, Blok BA, Joosten LA, et al. In Vitro Experimental Model of Trained Innate Immunity in Human Primary Monocytes. Clin Vaccine Immunol, 2016,23(12):926-933. doi: 10.1128/CVI.00349-16. doi: 10.1128/CVI.00349-16 URL pmid: 27733422
[57]	Kaufmann E, Sanz J, Dunn JL, et al. BCG Educates Hematopoietic Stem Cells to Generate Protective Innate Immunity against Tuberculosis. Cell, 2018, 172(1/2): 176-190. doi: 10.1016/j.cell.2017.12.031.
[58]	Mitroulis I, Ruppova K, Wang B, et al. Modulation of Myelopoiesis Progenitors Is an Integral Component of Trained Immunity. Cell, 2018, 172(1/2): 147-161. e12. doi: 10.1016/j.cell.2017.11.034.
[59]	Arts RJW, Carvalho A, La Rocca C, et al. Immunometabolic Pathways in BCG-Induced Trained Immunity. Cell Rep, 2016,17(10):2562-2571. doi: 10.1016/j.celrep.2016.11.011. doi: 10.1016/j.celrep.2016.11.011 URL pmid: 27926861

第一作者/参考文献	发表年份	研究类型	区域	人群	麻风病患者例数	卡介苗对麻风病保护效果
Stanley^[20]	1981	试验研究	乌干达	儿童	269	保护率为80% (95%CI:72%~86%)
Lwin^[21]	1985	试验研究	缅甸	儿童	663	保护率为20.4% (95%CI:12%~28%)
Bagshawe^[22]	1989	试验研究	新几内亚岛	各年龄段	281	保护率为48% (95%CI:34%~59%)
P?nnighaus^[23]	1992	试验研究	马拉维	各年龄段	414	保护率为50%
Rodrigues^[24]	1992	病例对照研究	巴西	<16岁	62	保护率为81%
Baker^[25]	1993	病例对照研究	马拉维	平均(22.1±6.0)岁	145	保护率为63.6% (95%CI:42.2%~77.2%)
Karonga Prevention Trial Group^[26]	1996	试验研究	马拉维	各年龄段	93	相对危险度为0.51 (95%CI:0.25~1.03)
Lombardi^[27]	1996	病例对照研究	巴西	<16岁	78	保护率为90% (95%CI:78%~96%)
Bertolli^[28]	1997	病例对照研究	缅甸	6~24岁	351	保护率为66% (95%CI:44%~80%)
Zodpey^[29]	1998	病例对照研究	印度	<32岁	314	比值比为0.29 (95%CI:0.21~0.41)
Zodpey^[30]	1999	病例对照研究	印度	<35岁	212	比值比为0.40 (95%CI:0.23~0.68)
Cunha^[31]	2004	队列研究	巴西	7~14岁	181	保护率为74% (95%CI:57%~86%)
Zodpey^[32]	2005	病例对照研究	印度	各年龄段	364	比值比为0.46 (95%CI:0.34~0.61)
Rahete^[33]	2007	病例对照研究	印度	成年人	201	比值比为0.65 (95%CI:0.40~1.04)
Zodpey^[34]	2007	病例对照研究	印度	成年人	292	比值比为0.38 (95%CI:0.26~0.55)
Düppre^[35]	2008	队列研究	巴西	各年龄段	1161	保护率为56% (95%CI:31%~71%)

第一作者/参考文献	发表年份	病毒	研究类型	国籍	患者例数	主要发现
Stensballe^[39]	2005	呼吸道合胞病毒	病例对照研究	几内亚、巴西	386	呼吸道合胞病毒患儿中未接种卡介苗的占比高于对照组(11.0% vs 5.8%),但差异无统计学意义
Arts^[40]	2018	黄热病毒	随机临床试验	-	30	接种卡介苗可以降低黄热病毒疫苗接种后的病毒血症
Hippmann^[41]	1992	单纯疱疹病毒	试验研究	-	109	全部单纯疱疹病毒患者接种卡介苗后4~6个月内未出现疱疹
Podder^[42]	2017	人乳头瘤病毒	随机临床试验	印度	60	接种卡介苗能够明显减少疣的数量,卡介苗组疣完全清除的比例优于结核菌素纯蛋白衍生物组
Leentjens^[43]	2015	流感病毒	随机临床试验	-	40	在接种流感病毒疫苗前接种卡介苗能够明显促进H1N1流感病毒功能性抗体的产生
Daulatabad^[44]	2016	人乳头瘤病毒	病例系列报告	-	7	7例患者中,接种卡介苗后疣减少的例数为6例,其中完全清除的例数为2例。但4例患者发生不良反应,包括接种部位肿胀、淋巴结肿大等
Salem^[49]	2013	人乳头瘤病毒	随机临床试验	-	80	与安慰剂组相比,局部接种卡介苗能够明显提高对疣的清除效果(P<0.001)